We are live on ! Find out more
GNCA

Genocea Biosciences, Inc.

Delisted

GNCA was delisted on the 2nd of June, 2022.

48 hedge funds and large institutions have $79.4M invested in Genocea Biosciences, Inc. in 2016 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 15 increasing their positions, 14 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

21% more capital invested

Capital invested by funds: $65.7M → $79.4M (+$13.7M)

7% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 14

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

16% less funds holding

Funds holding: 5748 (-9)

64% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 14

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $25K

Holders
48
Holders Change
-9
Holders Change %
-15.79%
% of All Funds
1.28%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
5
Increased
15
Reduced
14
Closed
14
Calls
Puts
$25K
Net Calls
-$25K
Net Calls Change
-$25K
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$21.8M +$59.8K +1,524 +0.3%
Franklin Resources
2
Franklin Resources
California
$15.5M
PVMCV
3
Polaris Venture Management Co V
Massachusetts
$10.1M
NC
4
Northpointe Capital
Michigan
$7.36M +$3.35M +85,284 +90%
DM
5
Deerfield Management
New York
$3.52M
Vanguard Group
6
Vanguard Group
Pennsylvania
$3.51M +$145K +3,684 +4%
SFM
7
Sphera Funds Management
Israel
$3.12M -$490K -12,500 -14%
Axa
8
Axa
France
$3.05M +$824 +21 +0%
RSCM
9
Rock Springs Capital Management
Maryland
$2.46M
AA
10
AlphaMark Advisors
Kentucky
$1.16M +$392 +10 +0%
Alyeska Investment Group
11
Alyeska Investment Group
Illinois
$1.15M +$43.7K +1,113 +4%
Principal Financial Group
12
Principal Financial Group
Iowa
$1.08M -$9.89K -252 -1%
BIT
13
BlackRock Institutional Trust
California
$941K
Geode Capital Management
14
Geode Capital Management
Massachusetts
$723K +$108K +2,753 +18%
BCM
15
Bridgeway Capital Management
Texas
$609K +$147K +3,750 +34%
Millennium Management
16
Millennium Management
New York
$519K -$320K -8,149 -39%
BFA
17
BlackRock Fund Advisors
California
$310K -$824 -21 -0.3%
California Public Employees Retirement System
18
California Public Employees Retirement System
California
$307K
Jacobs Levy Equity Management
19
Jacobs Levy Equity Management
New Jersey
$250K -$12.3K -313 -5%
Dimensional Fund Advisors
20
Dimensional Fund Advisors
Texas
$250K +$68.6K +1,749 +40%
BC
21
Birchview Capital
Vermont
$200K
EMG
22
Ellington Management Group
Connecticut
$200K +$191K +4,880 New
Goldman Sachs
23
Goldman Sachs
New York
$197K +$42.2K +1,075 +29%
Northern Trust
24
Northern Trust
Illinois
$177K +$33.2K +846 +24%
Ameriprise
25
Ameriprise
Minnesota
$172K -$90.7K -2,312 -44%

GNCA Hedge Fund Activity: Q3 2016 in Review

48 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Genocea Biosciences, Inc. (GNCA) for Q3 2016, worth a combined $79.4M — up 21% from $65.7M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of GNCA and 5 opened new positions — a net loss of 9 holders — while 14 trimmed existing stakes and 15 added.

The largest buyer was Northpointe Capital, adding an estimated $3.35M. The largest seller was AWM Investment Company, exiting entirely with an estimated $3.19M sold.

  • 48 institutional investors held Genocea Biosciences, Inc. (GNCA) as of Q3 2016, down from 57 in Q2 2016.
  • Funds reported $79.4M of Genocea Biosciences, Inc. stock for Q3 2016, up 21% quarter-over-quarter.
  • 5 funds opened new Genocea Biosciences, Inc. positions in Q3 2016 and 14 closed out, a net change of -9 holders.
  • The largest Genocea Biosciences, Inc. buyer in Q3 2016 was Northpointe Capital, an estimated $3.35M added.
  • The largest Genocea Biosciences, Inc. seller in Q3 2016 was AWM Investment Company, an estimated $3.19M sold.

Based on aggregated 13F filings for Q3 2016.